There is a bidirectional and complex relationship between the heart and kidneys. This interaction is physical, chemical as well as biological and is also reflected in a strong connection between renal and cardiovascular diseases. Cardiorenal syndrome type 4 (CRS type 4) is characterized by primary chronic kidney disease (CKD) leading to an impairment of cardiac function, with ventricular hypertrophy, diastolic dysfunction, and/or increased risk of adverse cardiovascular events. The incidence of CKD is increasing, and CRS type 4 is becoming a major public health problem associated with a high morbidity and mortality. In this study, we briefly review the epidemiology and pathophysiology of CRS type 4, the role of biomarkers in its early identification, and its management.

Keywords:
Cardiorenal syndrome type 4, Chronic kidney disease, Biomarkers, Cardiovascular events
1.
Ronco C, Chionh CY, Haapio M, Anavekar NS, House A, Bellomo R: The cardiorenal syndrome. Blood Purif 2009;27:114-126.
2.
Ronco C, Haapio M, House AA, Anavekar N, Bellomo R: Cardiorenal syndrome. J Am Coll Cardiol 2008;52:1527-1539.
3.
Ronco C, House AA, Haapio M: Cardiorenal syndrome: refining the definition of a complex symbiosis gone wrong. Intensive Care Med 2008;34:957-962.
4.
Ronco C, House AA, Haapio M: Cardiorenal and renocardiac syndromes: the need for a comprehensive classification and consensus. Nat Clin Pract Nephrol 2008;4:310-311.
5.
Garg AX, Clark WF, Haynes RB, House AA: Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. Kidney Int 2002;61:1486-1494.
6.
Sarnak MJ, Coronado BE, Greene T, Wang SR, Kusek JW, Beck GJ, Levey AS: Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol 2002;57:327-335.
7.
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-1305.
8.
Stenvinkel P, Barany P, Heimburger O, Pecoits-Filho R, Lindholm B: Mortality, malnutrition, and atherosclerosis in ESRD: what is the role of interleukin-6? Kidney Int Suppl 2002;80:103-108.
9.
Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154-2169.
10.
Ruggenenti P, Schieppati A, Remuzzi G: Progression, remission, regression of chronic renal diseases. Lancet 2001;357:1601-1608.
11.
Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001;134:629-636.
12.
Hallan SI, Stevens P: Screening for chronic kidney disease: which strategy? J Nephrol 2010;23:147-155.
13.
Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G: National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003;139:137-147.
14.
Muntner P, Anderson A, Charleston J, Chen Z, Ford V, Makos G, O'Connor A, Perumal K, Rahman M, Steigerwalt S, Teal V, Townsend R, Weir M, Wright JT Jr: Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis 2010;55:441-451.
15.
Thomas R, Kanso A, Sedor JR: Chronic kidney disease and its complications. Prim Care 2008;35:329-344.
16.
Hutchison JA: Vascular calcification in dialysis patients. Prilozi 2007;28:215-224.
17.
Kramer H, Toto R, Peshock R, Cooper R, Victor R: Association between chronic kidney disease and coronary artery calcification: the DALLAS Heart Study. J Am Soc Nephrol 2005;16:507-513.
18.
Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999;55:648-658.
19.
Noh H, Lee SW, Kang SW, Shin SK, Choi KH, Lee HY, Han DS: Serum C-reactive protein: a predictor of mortality in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1998;18:387-394.
20.
Schiffrin EL, Lipman ML, Mann JF: Chronic kidney disease: effects on the cardiovascular system. Circulation 2007;116:85-97.
21.
Meyer TW, Hostetter TH: Uremia. N Engl J Med 2007;357:1316-1325.
22.
Middleton JP, Pun PH: Hypertension, chronic kidney disease, and the development of cardiovascular risk: a joint primacy. Kidney Int 2010;77:753-755.
23.
Navab KD, Elboudwarej O, Gharif M, Yu J, Hama SY, Safarpour S, Hough GP, Vakili L, Reddy ST, Navab M, Vaziri ND: Chronic inflammatory disorders and accelerated atherosclerosis: Chronic kidney disease. Curr Pharm Des 2011;17:17-20.
24.
Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-1483.
25.
Hakim RM: Clinical implications of hemodialysis membrane biocompatibility. Kidney Int 1993;44:484-494.
26.
Amore A, Bonaudo R, Ghigo D, Arese M, Costamagna C, Cirina P, Gianoglio B, Perugini L, Coppo R: Enhanced production of nitric oxide by blood-dialysis membrane interaction. J Am Soc Nephrol 1995;6:1278-1283.
27.
Tielemans C, Husson C, Schurmans T, Gastaldello K, Madhoun P, Delville JP, Marchant A, Goldman M, Vanherweghem JL: Effects of ultrapure and non-sterile dialysate on the inflammatory response during in vitro hemodialysis. Kidney Int 1996;49:236-243.
28.
Ashby DR, Power A, Singh S, Choi P, Taube DH, Duncan ND, Cairns TD: Bacteremia associated with tunneled hemodialysis catheters: outcome after attempted salvage. Clin J Am Soc Nephrol 2009;4:1601-1605.
29.
Goldstein SL, Ikizler TA, Zappitelli M, Silverstein DM, Ayus JC: Non-infected hemodialysis catheters are associated with increased inflammation compared to arteriovenous fistulas. Kidney Int 2009;76:1063-1069.
30.
Agarwal R, Weir MR: Dry-weight: a concept revisited in an effort to avoid medication-directed approaches for blood pressure control in hemodialysis patients. Clin J Am Soc Nephrol 2010;5:1255-1260.
31.
Stegmayr BG: Ultrafiltration and dry weight - what are the cardiovascular effects? Artif Organs 2003;27:227-229.
32.
Chung SH, Heimburger O, Stenvinkel P, Wang T, Lindholm B: Influence of peritoneal transport rate, inflammation, and fluid removal on nutritional status and clinical outcome in prevalent peritoneal dialysis patients. Perit Dial Int 2003;23:174-183.
33.
Fassett RG, Driver R, Healy H, Coombes JS: Cardiovascular disease in peritoneal dialysis patients. Panminerva Med 2009;51:151-161.
34.
Mutluay R, Konca C, Erten Y, Pasaoglu H, Deger SM, Agirgun C, Derici U, Arinsoy T, Sindel S: Predictive markers of asymptomatic atherosclerosis in end-stage renal disease patients. Ren Fail 2010;32:448-454.
35.
Arikan H, Koc M, Tuglular S, Ozener C, Akoglu E: Elevated plasma levels of PAI-1 predict cardiovascular events and cardiovascular mortality in prevalent peritoneal dialysis patients. Ren Fail 2009;31:438-445.
36.
Daniels LB, Maisel AS: Natriuretic peptides. J Am Coll Cardiol 2007;50:2357-2368.
37.
DeFilippi CR, Fink JC, Nass CM, Chen H, Christenson R: N-terminal pro-B-type natriuretic peptide for predicting coronary disease and left ventricular hypertrophy in asymptomatic CKD not requiring dialysis. Am J Kidney Dis 2005;46:35-44.
38.
Codognotto M, Piccoli A, Zaninotto M, Mion MM, Ruzza L, Barchita A, Naso A, Plebani M: Effect of a dialysis session on the prognostic values of NT-proBNP, troponins, endothelial damage and inflammation biomarkers. J Nephrol 2010;23:465-471.
39.
Wang AY, Lam CW, Yu CM, Wang M, Chan IH, Zhang Y, Lui SF, Sanderson JE: N-terminal pro-brain natriuretic peptide: an independent risk predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic peritoneal dialysis patients. J Am Soc Nephrol 2007;18:321-330.
40.
Ooi DS, Zimmerman D, Graham J, Wells GA: Cardiac troponin T predicts long-term outcomes in hemodialysis patients. Clin Chem 2001;47:412-417.
41.
Dierkes J, Domrose U, Westphal S, Ambrosch A, Bosselmann HP, Neumann KH, Luley C: Cardiac troponin T predicts mortality in patients with end-stage renal disease. Circulation 2000;102:1964-1969.
42.
Mallamaci F, Zoccali C, Parlongo S, Tripepi G, Benedetto FA, Cutrupi S, Bonanno G, Fatuzzo P, Rapisarda F, Seminara G, Stancanelli B, Bellanuova I, Cataliotti A, Malatino LS: Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2002;40:68-75.
43.
Iwanaga Y, Miyazaki S: Heart failure, chronic kidney disease, and biomarkers - an integrated viewpoint. Circ J 2010;74:1274-1282.
44.
Ix JH, Shlipak MG, Chertow GM, Whooley MA: Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation 2007;115:173-179.
45.
Patel PC, Ayers CR, Murphy SA, Peshock R, Khera A, de Lemos JA, Balko JA, Gupta S, Mammen PP, Drazner MH, Markham DW: Association of cystatin C with left ventricular structure and function: the DALLAS Heart Study. Circ Heart Fail 2009;2:98-104.
46.
Hemdahl AL, Gabrielsen A, Zhu C, Eriksson P, Hedin U, Kastrup J, Thoren P, Hansson GK: Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction. Arterioscler Thromb Vasc Biol 2006;26:136-142.
47.
Yndestad A, Landro L, Ueland T, Dahl CP, Flo TH, Vinge LE, Espevik T, Froland SS, Husberg C, Christensen G, Dickstein K, Kjekshus J, Oie E, Gullestad L, Aukrust P: Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. Eur Heart J 2009;30:1229-1236.
48.
Zografos T, Haliassos A, Korovesis S, Giazitzoglou E, Voridis E, Katritsis D: Association of neutrophil gelatinase-associated lipocalin with the severity of coronary artery disease. Am J Cardiol 2009;104:917-920.
49.
Koomans HA, Blankestijn PJ, Joles JA: Sympathetic hyperactivity in chronic renal failure: a wake-up call. J Am Soc Nephrol 2004;15:524-537.
50.
Schmieder RE, Delles C, Mimran A, Fauvel JP, Ruilope LM: Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care 2007;30:1351-1356.
51.
Pun PH, Lehrich RW, Smith SR, Middleton JP: Predictors of survival after cardiac arrest in outpatient hemodialysis clinics. Clin J Am Soc Nephrol 2007;2:491-500.
52.
Dohi Y, Ohashi M, Sugiyama M, Takase H, Sato K, Ueda R: Candesartan reduces oxidative stress and inflammation in patients with essential hypertension. Hypertens Res 2003;26:691-697.
53.
Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
54.
Takahashi A, Takase H, Toriyama T, Sugiura T, Kurita Y, Ueda R, Dohi Y: Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis - a randomized study. Nephrol Dial Transplant 2006;21:2507-2512.
55.
Suzuki H, Kanno Y, Sugahara S, Ikeda N, Shoda J, Takenaka T, Inoue T, Araki R: Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am J Kidney Dis 2008;52:501-506.
56.
Chonchol M, Benderly M, Goldbourt U: Beta-blockers for coronary heart disease in chronic kidney disease. Nephrol Dial Transplant 2008;23:2274-2279.
57.
Cice G, Ferrara L, D'Andrea A, D'Isa S, Di Benedetto A, Cittadini A, Russo PE, Golino P, Calabro R: Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 2003;41:1438-1444.
58.
Koch M, Thomas B, Tschope W, Ritz E: Survival and predictors of death in dialysed diabetic patients. Diabetologia 1993;36:1113-1117.
59.
Ritz E, Dikow R, Adamzcak M, Zeier M: Congestive heart failure due to systolic dysfunction: The Cinderella of cardiovascular management in dialysis patients. Semin Dial 2002;15:135-140.
60.
Borazan A, Ustun H, Ustundag Y, Aydemir S, Bayraktaroglu T, Sert M, Yilmaz A: The effects of peritoneal dialysis and hemodialysis on serum tumor necrosis factor-alpha, interleukin-6, interleukin-10 and C-reactive-protein levels. Mediators Inflamm 2004;13:201-204.
61.
Pupim LB, Himmelfarb J, McMonagle E, Shyr Y, Ikizler TA: Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress. Kidney Int 2004;65:2371-2379.
62.
Macleod AM, Campbell M, Cody JD, Daly C, Donaldson C, Grant A, Khan I, Rabindranath KS, Vale L, Wallace S: Cellulose, modified cellulose and synthetic membranes in the haemodialysis of patients with end-stage renal disease. Cochrane Database Syst Rev 2005:CD003234.
63.
House AA, Wells GA, Donnelly JG, Nadler SP, Hebert PC: Randomized trial of high-flux vs low-flux haemodialysis: effects on homocysteine and lipids. Nephrol Dial Transplant 2000;15:1029-1034.
64.
Chauveau P, Nguyen H, Combe C, Chene G, Azar R, Cano N, Canaud B, Fouque D, Laville M, Leverve X, Roth H, Aparicio M: Dialyzer membrane permeability and survival in hemodialysis patients. Am J Kidney Dis 2005;45:565-571.
65.
Gerdemann A, Wagner Z, Solf A, Bahner U, Heidland A, Vienken J, Schinzel R: Plasma levels of advanced glycation end products during haemodialysis, haemodiafiltration and haemofiltration: potential importance of dialysate quality. Nephrol Dial Transplant 2002;17:1045-1049.
66.
Lin CL, Yang CW, Chiang CC, Chang CT, Huang CC: Long-term on-line hemodiafiltration reduces predialysis beta-2-microglobulin levels in chronic hemodialysis patients. Blood Purif 2001;19:301-307.
67.
Canaud B, Morena M, Leray-Moragues H, Chalabi L, Cristol JP: Overview of clinical studies in hemodiafiltration: what do we need now? Hemodial Int 2006;10(suppl 1):S5-S12.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.